Criteria for cure of acromegaly: A consensus statement

Journal of Clinical Endocrinology and Metabolism

Volumn 85, Issue 2, 2000, Pages 526-529

  Giustina, Andrea ^a   Barkan, Ariel ^b   Casanueva, Felipe F ^c   Cavagnini, Franco ^d   Frohman, Lawrence ^e   Ho, Ken ^f   Veldhuis, Johannes ^g   Wass, John ^h   Von Werder, Klaus ⁱ   Melmed, Shlomo ^j,k  

^a UNIVERSITY OF BRESCIA   (Italy)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

^c UNIVERSITY OF SANTIAGO DE COMPOSTELA   (Spain)

^d UNIVERSITY OF MILAN   (Italy)

^e UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

^f ST VINCENT S HOSPITAL   (Australia)

^g UNIVERSITY OF VIRGINIA   (United States)

^h RADCLIFFE INFIRMARY   (United Kingdom)

ⁱ Schlosspark Klinik   (Germany)

^j UNIVERSITY OF CALIFORNIA   (United States)

^k CEDARS SINAI MEDICAL CENTER   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOPEPTIN; GLUCOSE; GONADORELIN; OCTREOTIDE; PROTIRELIN; SOMATOMEDIN C; SOMATOSTATIN RECEPTOR;

ACROMEGALY; ADENOMA; DISEASE CONTROL; GROWTH HORMONE RELEASE; HUMAN; ITALY; ORAL GLUCOSE TOLERANCE TEST; ORGANIZATION; PRIORITY JOURNAL; REVIEW; TREATMENT OUTCOME;

ACROMEGALY; GLUCOSE TOLERANCE TEST; GOALS; HUMAN GROWTH HORMONE; HUMANS; MORBIDITY; NEUROSURGERY; RADIOTHERAPY; SOMATOMEDINS; TREATMENT OUTCOME;

BRESCIA;

EID: 17744371632     PISSN: 0021972X     EISSN: None     Source Type: Journal    
DOI: 10.1210/jc.85.2.526     Document Type: Review

References (32)

1. Characterization of 24-hour growth hormone secretion in acromegaly: Implications for diagnosis and therapy
2. Enhanced sensitivity growth hormone (GH) chemiluminescence assay reveals lower post-glucose nadir GH concentrations in men than women
3. Current treatment guidelines for acromegaly
4. Investigation protocol: Acromegaly and its investigation
5. Diagnosis and endocrine testing in acromegaly
6. Evaluation of disease status with sensitive measures of GH secretion in 60 post-operative patients with acromegaly
7. Increase of serum growth hormone concentration following thyrotropin-releasing hormone injection in patients with acromegaly or gigantism
8. Effects of growth hormone-releasing factor on growth hormone secretion in acromegaly
9. Detection of doping with human growth hormone
10. Insulin-like growth factors, and their binding proteins: Biological actions
11. Serum insulin-like growth factor-binding protein-3 levels in the diagnosis of acromegaly
12. Complications of transsphenoidal surgery: Results of a national survey, review of the literature, and personal experience
13. Long-term endocrinological follow-up evaluation in 115 patients who underwent transsphenoidal surgery for acromegaly
14. Long-term mortality after transsphenoidal surgery, and adjunctive therapy for acromegaly
15. Transsphenoidal microsurgery for growth hormone-secreting pituitary adenomas: Initial outcome and long-term results
16. Results of surgical treatment for growth hormone-secreting adenomas
17. Pituitary surgery in advances in pituitary tumor therapy
18. Octreotide
19. Octreotide as primary therapy for acromegaly
20. Results of a European multicentre study with Sandostatin LAR in acromegalic patients
21. Three-year follow-up of acromegalic patients treated with intramuscular slow-release lanreotide
22. Treatment of acromegaly with dopamine agonists
23. Cabergoline in the treatment of acromegaly: A study in 64 patients
24. In vitro and in vivo studies of antagonistic effects of human growth hormone analogs
25. Radiation therapy of acromegaly
26. Pituitary irradiation is ineffective in normalizing plasma insulin-like growth factor I in patients with acromegaly
27. Stereotactic radiosurgery for recurrent surgically treated acromegaly, comparison with fractionated radiotherapy
28. Determinants of clinical outcome and survival in acromegaly
29. An audit of outcome of treatment in acromegaly
30. Does treatment of acromegaly affect life expectancy?
31. Acromegaly, colonic polyps and carcinoma
32. Tight control of growth hormone: An attainable outcome for acromegaly treatment